Atezolizumab,Carboplatin,Etoposide,Tiragolumab
Roche
['kudos', 'skyscraper-02', 'lcsm,(-blcsm)', 'improve ', 'paradigm']
results from #skyscraper-02 presented at #asco22 #lcsm , aim to build on the current paradigm of chemo + pd1, w/tigit pfs os coprimary endpoint no benefit for the comb disappointing but kudos to pis and pts as we cont to try and improve 
Leslye M. Heisler Associate Professor of Lung Cancer Excellence @PennMedicine | Faculty @PC31 | Associate Director @PennPrecisMed | Tweets my own